Biopharma News
Baxter to Split Into Biopharmaceuticals and Medical Products Companies
Baxter announces plans to split into two independent companies by mid-2015.
XstalBio Launches Vaccine Analysis Service
XstalBio Analytics' approach to vaccine analysis and formulation is aimed at understanding the antigen– adjuvant interaction.
FDA approves Novartis' Xolair for Rare Skin Disease
FDA approves Xolair (omalizumab) for the treatment of a rare skin disease known as chronic idiopathic urticarial.
Cobra Biologics and BioCancell Collaborate on Cancer Therapy Drug
Cobra Biologics and BioCancell announce an agreement to manufacture BioCancell's BC-821 cancer drug.
Novartis Recognizes Rare Disease Day
Novartis calls for more research to understand and find treatments for rare disease.
Debiopharm Group to Acquire Affinium Antibiotic Clinical Assets
Debiopharm acquires Affinium's clinical and preclinical assets and its technology platform.
PharmaCell to Purchase Cell Therapy Production Facility from TiGenix
PharmaCell enters an agreement purchase TiGenix therapy production facility.
Teva to Expand Central Nervous System Portfolio with Acquisition of NuPathe
Teva announced an agreement to acquire NuPathe and its migraine treatment patch.
Sanofi and Fraunhofer Create Center to Accelerate Antibiotic Research
The Natural Product Center of Excellence seeks to identify novel active compounds for new antibiotics.
The Carlyle Group Agrees to Acquire Johnson & Johnson#39;s Ortho-Clinical Diagnostics Business
J&J's diagnostics business goes to global asset manager, The Carlyle Group.
CBR–SYNARC and BioClinica Merge And Appoint New Chairman
CCBR–SYNARC and BioClinica merge to create a provider of specialized outsourced clinical services.
CytomX Therapeutics and ImmunoGen to Develop Probody-Drug Conjugates
CytomX Therapeutics and ImmunoGen announce collaboration to develop probody-drug conjugate therapies for the treatment of cancer.
Hemispherx Biopharma Reports Clinical Potential of Treatment for Drug-Resistant Influenza Virus
Research was published describing a natural interferon-alpha for infection control and treatment of drug-resistant H7N9 influenza.
Zymeworks, ImClone Systems to Develop Bi-specific Antibodies
Zymeworks has entered into a licensing and collaboration agreement with ImClone Systems to develop novel bi-specific antibody oncology therapeutics.
Genzyme Receives Complete Response Letter from FDA on Lemtrada Application
Genzyme plans to appeal FDA?s decision that the multiple-sclerosis treatment is not ready for approval.
Pfizer Appoints Head of Vaccines
Pfizer appoints management changes to take effect in 2014.
Pfizer, Siemens Partner in Companion Diagnostics
Siemens enters agreement with Pfizer to commercialize diagnostic tests for therapeutic products across Pfizer's pipeline.
ProBioGen, Emergent BioSolutions Partner in Vaccine Manufacturing
ProBioGen signs agreement with Emergent BioSolutions for access to ProBioGen's avian AGE1.CR cell line.
MedImmune Collaborates with Johns Hopkins University
AstraZeneca's MedImmune will collaborate with Johns Hopkins University in both biologics and small-molecule projects.
Merck KGaA Expands German Production Facility for Allergopharma Unit
Merck's new facility for aseptic production in Reinbek, Germany is scheduled to be completed in 2016.
J&J Innovation Announces Opening of Offices
Johnson&Johnson will open a network of partnering offices across the UK.
Pfizer, Octopharm Partner
Octapharma and Pfizer form an agreement for the future marketing and commercialization of human prothrombin complex concentrate.
GSK Launches Cancer Research Consortium
GSK forms the Oncology Clinical and Translational Consortium, a scientific research network comprised of six international cancer centers.
BMS Names New Board Member
Bristol-Myers Squibb has elected Thomas Lynch, Jr., MD to its board of directors.
Lilly Funds Start Up of Biosciences Research Institute
The Indiana Biosciences Research Institute will accelerate collaboration and focus on human-health solutions.
Merck KGaA Invests in Research Partnerships in Israel
Additional companies join Merck KGaA and Neviah Genomics in the Israel BioIncubator.
Merck KGaA Invests in China, Global HQ
Merck KGaA plans to build a new biomanufacturing facility in Nantong, China.
Shire To Acquire Rare-Disease Company ViroPharma
Shire's agreement to acquire ViroPharma will strengthen its rare-disease portfolio.
Novartis Announced as Facility of the Year Awards Overall Winner
ISPE names Novartis' US Flu Cell Culture facility as award winner.
FDA Grants KaloBios Pharmaceuticals Orphan Drug Designation for KB001-A
KaloBios Pharmaceuticals receives FDA Orphan Drug Designation for KB001-A in treatment of cystic fibrosis patients.
